{"id":79782,"date":"2026-05-11T13:37:11","date_gmt":"2026-05-11T13:37:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/79782\/"},"modified":"2026-05-11T13:37:11","modified_gmt":"2026-05-11T13:37:11","slug":"mark-zuckerberg-backed-cellular-intelligence-acquires-novo-nordisks-parkinsons-cell-therapy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/79782\/","title":{"rendered":"Mark Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk’s Parkinson’s cell therapy"},"content":{"rendered":"

Meta CEO Mark Zuckerberg<\/a> backed-Cellular Intelligence has acquired Danish drugmaker Novo Nordisk<\/a>‘s cell therapy candidate for Parkinson’s disease, the biotech firm said on Monday.<\/p>\n

Last October, Novo Nordisk had shut down its cell therapy unit as part of a broader restructuring, discontinuing development \u200cof \u2060the therapy.<\/p>\n

Here \u2060are some details:<\/p>\n

Financial terms of the agreement were \u200bnot disclosed. Novo will take an equity stake in Cellular and could \u200breceive future milestone payments and royalties, the biotech firm said.<\/p>\n

The treatment, named STEM-PD, an allogeneic, stem cell-derived \u200btherapy, designed to replace dopamine-producing nerve \u2060cells lost \u200cin Parkinson’s disease.<\/p>\n

Parkinson’s is a \u200bprogressive brain \u200bdisorder, leading to symptoms such as tremors, \u2060stiffness and slow movement.<\/p>\n

Cellular said it intends \u200bto apply its proprietary AI platform to \u200bspeed up the treatment’s development, scale manufacturing and reduce costs. The data will be used to further train the AI model.<\/p>\n

“It marks the beginning of an AI-native era for cell replacement therapy, one where biology \u200cis no longer destiny, but design,” said Cellular’s CEO Micha Breakstone.<\/p>\n

The treatment is being tested in a early-to-mid \u2060stage trial and has received the fast-track designation from the U.S. Food and Drug Administration<\/a>, a status meant to expedite the review of therapies for serious conditions with unmet medical needs.<\/p>\n

Cellular Intelligence<\/a> has raised more than $60 million from investors including Khosla Ventures<\/a> and the Chan Zuckerberg Initiative<\/a>, a philanthropic organisation founded by Zuckerberg.<\/p>\n","protected":false},"excerpt":{"rendered":"Meta CEO Mark Zuckerberg backed-Cellular Intelligence has acquired Danish drugmaker Novo Nordisk‘s cell therapy candidate for Parkinson’s disease,…\n","protected":false},"author":2,"featured_media":79783,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[42456,42452,42458,42461,42457,21278,272,42459,42460,2436],"class_list":{"0":"post-79782","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-ai-in-medicine","9":"tag-cellular-intelligence","10":"tag-chan-zuckerberg-initiative","11":"tag-fda-fast-track-designation","12":"tag-khosla-ventures","13":"tag-mark-zuckerberg","14":"tag-novo-nordisk","15":"tag-parkinsons-disease-treatment","16":"tag-stem-cell-therapy","17":"tag-u-s-food-and-drug-administration"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116556218193024980","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/79782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=79782"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/79782\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/79783"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=79782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=79782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=79782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}